spacer
home > ebr > spring 2019 > the authenticity of synthetics
PUBLICATIONS
European Biopharmaceutical Review

The Authenticity of Synthetics

Synthetic biology is a newly coined term for the design and construction of novel artificial biological pathways, organisms, or devices or the redesign of existing natural biological systems (1). Generally, it assumes an element of scale and the application of engineering-like techniques to solve biological problems through a rational process of ‘biodesign’. The field of synthetic biology brings together skills from biology and chemistry to computing, bioinformatics, and engineering. This emerging field is greatly anticipated to deliver significant and broad impact across a range of potential applications, among them the drug discovery and development field. However, to achieve its full potential, synthetic biology will require the continued development and convergence of its underlying skills and disciplines to enable the rational and predictable design of biological systems. As DNA is a fundamental building block of synthetic biology, the key to its success will be the ability to synthesise DNA at scale and with high accuracy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Tim Brears is CEO at Evonetix, where he leads the company in developing a benchtop DNA writer to transition DNA synthesis from a service industry to one where scientists can make genes at will. He holds a PhD from the University of Cambridge, UK, and has an MBA from Duke University’s Fuqua School of Business, US.
spacer
Dr Tim Brears
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharmapack success points to sizeable growth potential for global drug delivery and packaging in 2019

Paris, 19th March 2019: The drug delivery and healthcare packaging industry is set for significant growth in 2019 as Pharmapack Europe (#pharmapackeu) – a key bellwether of industry health – welcomed a record 410 exhibiting companies and nearly 5,500 attendees from 75 countries. Europe’s biggest pharmaceutical packaging and drug delivery event (Paris Expo, Porte de Versailles, France 6-7 February, 2019) saw a diversification of innovations and new drug delivery solutions, with ‘patient-centricity’ emerging as the central theme throughout this year’s edition.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement